Clinical Trials on Wet Age-related Macular Degeneration in Switzerland

Total 146 results

Berner Augenklinik
medignition AG

Enrolling by invitation

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (SPARROW)

Wet Age-related Macular Degeneration

Switzerland
Bayer
Regeneron Pharmaceuticals

Completed

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)

Wet Age-related Macular Degeneration

Switzerland
Vista Klinik
Novartis

Terminated

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept (ROBIN)

Neovascular Age-related Macular Degeneration

Switzerland
Allergan
Molecular Partners AG

Terminated

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Wet Age-Related Macular Degeneration

Switzerland, France, Czech Republic
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Novartis

Completed

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

United Kingdom, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Hoffmann-La Roche

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal)

Neovascular Age-Related Macular Degeneration

Belgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Hoffmann-La Roche

Recruiting

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Neovascular Age-related Macular Degeneration (nAMD)

Belgium, Korea, Republic of, Germany, Spain, United Kingdom, Australia, Italy, Argentina, Israel, Austria, Brazil, France, Singapore, Switzerland, Taiwan, Turkey
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (OCTAVE)

Neovascular Age-related Macular Degeneration

Germany, Turkey, Austria, Canada, Czechia, United Kingdom, Hungary, Italy, Lithuania, Guatemala, France, Ireland, Argentina, Portugal, Spain, Sweden, Greece, Switzerland, Slovakia, Finland, Netherlands, Colombia, Mexico, Panama
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

Neovascular Age-related Macular Degeneration

United States, Korea, Republic of, United Kingdom, Japan, Canada, Turkey, Argentina, Australia, Denmark, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Israel, Portugal, Russian Federation, Ta... and more
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

United States, Spain, Korea, Republic of, Czechia, Japan, Singapore, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Bulgaria, Portugal, Latvia, Canada, Hungary, Arge... and more
Bayer

Terminated

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (DREAM)

Macular Degeneration

Hong Kong, Korea, Republic of, United States, Canada, Switzerland, Spain, Japan, Italy, Czech Republic, Australia, Austria, Slovakia, Germany, Hungary, Israel, Chile, France, Colombia
Novartis Pharmaceuticals

Completed

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications (PACIFIC)

Neovascular (Wet) Age-related Macular Degeneration

Germany, Switzerland, Netherlands
University Hospital Inselspital, Berne

Active, not recruiting

The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)

Age Related Macular Degeneration

Switzerland
University Hospital Inselspital, Berne

Completed

FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment (FLOS)

Age Related Macular Degeneration

Switzerland
University Hospital Inselspital, Berne

Completed

Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

Age Related Macular Degeneration

Switzerland
Augenklinik Zurich West
Apellis Pharmaceuticals, Inc.

Recruiting

Virtual Reality Based Vision Test in Patients With AMD (GA-001)

Age-Related Macular Degeneration

Switzerland
Dr. med. Katja Hatz
Cenaug Foundation

Completed

Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment

Neovascular Age-related Macular Degeneration

Switzerland
University Hospital Inselspital, Berne
Novartis

Completed

Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)

Age Related Macular Degeneration

Switzerland
University Hospital Inselspital, Berne

Completed

The Role of Macular Pigment in Patients With Age-related Macular Degeneration

Age Related Maculopathy

Switzerland
University Hospital Inselspital, Berne

Completed

Enhancement of Macular Pigment Density by Oral Lutein Supplementation (EMPOLS)

Age-Related Maculopathies

Switzerland
Vista Klinik

Completed

Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis
QLT Inc.

Completed

Photodynamic Therapy in Occult-Only Lesions (POOL)

Age-Related Macular Degeneration

Switzerland
Novartis

Completed

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis

Completed

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)

Age Related Macular Degeneration

Switzerland
Novartis

Completed

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Macular Degeneration (ARMD)

Switzerland
Vista Klinik

Completed

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
University Hospital, Basel, Switzerland

Completed

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Age-Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (SALT)

Neovascular Age-related Macular Degeneration

Germany, Austria, Belgium, Denmark, Switzerland, France, Netherlands, Portugal, Sweden, Norway
University of Southampton
King's College London; Medical University of Vienna; University of Michigan; Imperial... and other collaborators

Active, not recruiting

Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE (PINNACLE)

Age-related Macular Degeneration

Austria, Switzerland, United Kingdom
Allergan

Completed

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration

United States, Italy, Australia, Israel, Germany, Austria, France, Switzerland
Institute of Molecular and Clinical Ophthalmology...
Boehringer Ingelheim

Active, not recruiting

Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study (OMEGA)

Age-Related Macular Degeneration | Geographic Atrophy | Visual Field Defect, Central Scotoma of Both Eyes

Switzerland
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia
Association for Innovation and Biomedical Research...
European Vision Institute Clinical Research Network

Active, not recruiting

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression (INTERCEPT-AMD)

Atrophy | Age Related Macular Degeneration | Prediction | Intermediate AMD

Portugal, France, Germany, Ireland, Italy, Netherlands, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Terminated

Global Atrophie Biomarker Evaluation Study (GABiE) (GABiE)

Age-related Macular Degeneration

United States, Switzerland
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Germany, Croatia, Japan, United Kingdom, Spain, United States, Italy, Switzerland, Canada, France, Australia, Singapore, Israel, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
University Hospital Inselspital, Berne

Terminated

Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina

Age-related Macular Degeneration | Macular Edema | Retinal Vein Occlusion | Central Serous Chorioretinopathy | Retinal Neovascularization

Switzerland
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Wet Macular Degeneration

United Kingdom, Germany, Japan, Netherlands, United States, Canada, Hungary, Italy, Mexico, Poland, Spain, Israel, Russian Federation, Switzerland, Turkey
Hoffmann-La Roche

Terminated

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)

Geographic Atrophy

Canada, United States, Belgium, Peru, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Poland, Slovakia, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Terminated

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)

Geographic Atrophy

United States, United Kingdom, Netherlands, Germany, Belgium, Poland, Spain, Argentina, Australia, Hungary, Italy, Portugal, France, Turkey, Austria, Russian Federation, Mexico, Peru, Denmark, Slovakia, Sweden, Switzerland
Hoffmann-La Roche

Terminated

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Geographic Atrophy

United States, United Kingdom, Germany, France, Turkey, Australia, Austria, Belgium, Canada, Denmark, Hungary, Italy, Poland, Slovakia, Spain, Switzerland, Portugal, Netherlands, Peru
Novartis Pharmaceuticals

Completed

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

Age-related Macular Degeneration | Choroidal Neovascularization

Korea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
Novartis

Completed

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement (RESOLVE)

Diabetic Macular Edema

Switzerland
University Hospital Inselspital, Berne

Terminated

Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study) (AVOCT)

Diabetic Macular Edema

Switzerland
University Hospital Inselspital, Berne
University of Bern

Completed

Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema

Diabetic Macular Edema

Switzerland

Clinical Trials on Wet Age-related Macular Degeneration in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations